What Happened?
Montreal, PQ-based Inversago-Pharma Appointed François Ravenelle as Chief Executive Officer and Founder
About the Company
A specialized, preclinical-stage biotech company, Inversago Pharma develops new generations of peripherally-restricted cannabinoid-1 receptor (CB1) inverse agonists/ antagonists for the treatment of Prader-Willi Syndrome, diabetes, obesity and other metabolic disorders such as non-alcoholic steatohepatitis (NASH).
About the Person
François Ravenelle is Chief Executive Officer and Founder at Inversago Pharma. Previously, François held various senior HR leadership roles in the industry.
Info Source
News
Short Profile